Stock code: 300759.SZ

Stock code: 3759.HK

2025

Third Quarterly Results

October 2025Disclaimer

The documents opinions and materials presented in this presentation (the “Document”) have been prepared by Pharmaron Beijing Co. Ltd. (康龍化成(北京)新藥技術股份有限公司) (the “Company”) for use in

presentations by the Company and does not constitute a recommendation regarding the securities of the Company. You fully understand that the Document is being made available on a confidential basis and subject to

the following provisions. The contents of this Document have not been reviewed by any regulatory authority in any jurisdiction. The distribution of this Document in certain jurisdictions may be restricted by law and the

recipients into whose possession this Document comes should inform themselves about and observe such restrictions. By accessing this Document you are agreeing (i) that you have read and agree to comply with the

contents of this notice and disclaimer and (ii) to maintain absolute confidentiality regarding the information disclosed in this Document.This Document has not been independently verified and is not intended to form the basis of any investment decision. It does not constitute an offer or invitation to sell or any solicitation of any offer to subscribe for or

purchase any securities in any jurisdiction in which the making of such offer solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction or would not otherwise

be in compliance with the laws and regulations of such jurisdiction and nothing contained herein shall form the basis of any investment decision contract or commitment whatsoever. This Document contains no

information or material which may result in it being deemed (1) to be an advertisement invitation or document containing an advertisement or invitation falling within the meaning of section 103 of the Securities and

Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “Securities and Futures Ordinance”) or (2) in Hong Kong to have effected an offer to the public without compliance with the laws of Hong Kong or being

able to invoke any exemption available under the laws of Hong Kong and is subject to material change without notice.The securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933 as amended (the “U.S. Securities Act”) or under the laws of any state of the United States. This Document

does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States and is not for distribution and may not be distributed directly or indirectly in or into the United

States (including its territories and possessions any state of the United States and the District of Columbia). The securities of the Company will not be offered or sold in the United States except pursuant to an

exemption from or in a transaction not subject to the registration requirements of the U.S. Securities Act. There will be no public offer of the Company’s securities in the United States.This Document and the information contained herein as well as information presented orally or otherwise are strictly confidential and must be treated as such. Neither the information contained in this Document nor any

copy hereof may be directly or indirectly taken or transmitted into or distributed in the United States Canada Australia Japan PRC Hong Kong or any other jurisdiction which prohibits the same except in compliance

with applicable securities laws. Any failure to comply with this restriction may constitute a violation of U.S. or other jurisdiction's securities laws. Upon request the recipient will promptly return this Document and any

other written information made available in the presentation without retaining any copies.This Document does not purport to be comprehensive or to contain all the information that a recipient may need in order to evaluate the Group. No representation warranty or undertaking express or implied is given

and so far as is permitted by law no responsibility or liability is accepted by any person (for the avoidance of doubt including but not limited to the Company and its affiliates controlling persons directors officers

partners employees agents representatives or advisers of any of the foregoing) with respect to the accuracy reliability correctness fairness or completeness of this Document or its contents. The information

communicated in this presentation contains certain statements that are or may be forward looking. These statements typically contain words such as "will" "expects" “intends” “plans to” and "anticipates" and words of

similar import. These forward-looking statements reflects the current view of the Company with respect to future events are based on a number of assumptions about the Company’s operations and factors beyond the

Company’s control and are subject to significant risks and uncertainties and accordingly actual results may differ materially from these forward-looking statements. In particular but without limitation no representation

or warranty is given as to the achievement or reasonableness of and no reliance should be placed on any assumptions projections targets estimates forecasts or any forward-looking statements contained in this

Document. Each of the Company and its affiliates controlling persons directors officers partners employees agents representatives or advisers of any of the foregoing assumes no obligation to update or otherwise

revise these forward-looking statements for new information events or circumstances that occur subsequent to such dates. None of the Company and any of its affiliates controlling persons directors officers partners

employees agents representatives or advisers of any of the foregoing shall have any liability (in negligence or otherwise) in respect of the use of or reliance upon the information contained herein by you or any person

to whom the information herein is disclosed.In furnishing this Document the Company and its affiliates undertake no obligation to provide any additional information or to update this Document or any additional information or to correct any inaccuracies which may

become apparent.

23Q2025 Revenue & Profit Achieved Solid Growth QoQ & YoY

RMB mm 3Q2025 2Q2025 QoQ 3Q2024 YoY

Revenue 3645 3342 9.1% 3213 13.4%

Net Profit 440 396 11.0% 308 42.5%

Non-IFRSs Adjusted Net Profit 471 406 15.9% 417 12.9%

? Revenue and profit achieved solid growth QoQ & YoY

? Non-IFRSs adjusted net profit margin improved QoQ as a result of increased revenue

Data are rounded to the nearest million. Above financials are unaudited 31-3Q2025 Financials & Full-Year Outlook

RMB mm 1-3Q2025 1-3Q2024 YoY

Revenue 10086 8817 14.4%

Net Profit 1141 1422 -19.8%

Non-IFRSs Adjusted Net Profit 1227 1107 10.8%

? New POs: new POs increased by 13%+ YoY. Growth accelerated vs. 1H2025

? MNC Customers: revenue from TOP20 Pharmas increased by 37.9% YoY

? Cash Flow: net operating cash flow of RMB2.44 billion & free cash flow of RMB536 million

? Guidance: raise full-year guidance to 12~16% revenue growth

Data are rounded to the nearest million. Above financials are unaudited. Guidance does not include the potential contribution from the Biortus acquisition 41-3Q2025 Revenue Compositions

Segments Revenue Composition Global Customers Revenue Composition

Biologics & CGT ROW 2%

Services 3% NA Revenue Grew 11.9%

Clinical

Development China

Services 14% EU Revenue Grew 23.2% 15%

CN Revenue Grew 16.1% North

Laboratory

Europe America Services

64%

60%19%

Small Molecule

CDMO Services

23%

China/Overseas Entities Revenue Composition Diversified Customer Base Revenue Composition

New Customers

3%

China Entities Overseas TOP20 Pharmas TOP20

Subsidiaries

Revenue Grew 14.8% Revenue Grew 37.9% Pharmas

12%18%

Overseas Subsidiaries Other Customers

Revenue Grew 11.6% Revenue Grew 10.3%

China Other Repeat

Entities 88% Customers

79%

5Laboratory Services

RMB mm 3Q2025 2Q2025 QoQ 3Q2024 YoY 1-3Q2025 1-3Q2024 YoY

Revenue 2111 2035 3.7% 1847 14.3% 6004 5219 15.0%

GPM 45.0% 44.9% 0.1pct 45.3% -0.3pct 45.1% 44.8% 0.3pct

? Lab chemistry services & bioscience services both achieved rapid revenue growth YoY

? New POs increased by 12%+ YoY. Growth accelerated vs. 1H2025

Data are rounded to the nearest million. Above financials are unaudited 6CMC (Small Molecule CDMO) Services

RMB mm 3Q2025 2Q2025 QoQ 3Q2024 YoY 1-3Q2025 1-3Q2024 YoY

Revenue 903 697 29.6% 801 12.7% 2293 1977 16.0%

GPM 34.6% 30.6% 4.0pct 34.5% 0.1pct 32.1% 30.8% 1.3pct

? New POs increased by ~20% YoY

? The segment's revenue & GPM are expected to continue to increase in 4Q2025

Data are rounded to the nearest million. Above financials are unaudited 7Clinical Development Services

RMB mm 3Q2025 2Q2025 QoQ 3Q2024 YoY 1-3Q2025 1-3Q2024 YoY

Revenue 501 492 1.7% 463 8.2% 1440 1306 10.3%

GPM 10.8% 12.8% -2.0pct 14.4% -3.6pct 11.8% 13.2% -1.4pct

? Clinical development services in CN as well as radio-labelled science services and early-

stage clinical trial services in UK & US both achieved steady revenue growth YoY

? GPM declined due to revenue mix of different projects & competitions in China market

Data are rounded to the nearest million. Above financials are unaudited 8Biologics & CGT Services

RMB mm 3Q2025 2Q2025 QoQ 3Q2024 YoY 1-3Q2025 1-3Q2024 YoY

Revenue 125 113 10.6% 100 25.1% 336 311 8.1%

GPM -39.7% -42.3% 2.6pct -67.1% 27.4pct -49.1% -42.8% -6.3pct

? In 3Q2025 biologics CDMO services in CN and CGT CDMO services in UK & US both

achieved rapid revenue growth YoY

? The segment is in early-stage development. The launch of the biologics CDMO facility in

Ningbo in 2Q2024 resulted in increased operating costs and depreciation in 1-3Q2025

Data are rounded to the nearest million. Above financials are unaudited 91-3Q2025 Expenses for the Period

Selling and Distribution Expenses as % of Total Revenue Administrative Expenses as % of Total Revenue (1)

13.4%12.7%12.8%13.2%12.9%

2.2%2.2%2.1%2.1%2.2%

2022 2023 2024 1-3Q2024 1-3Q2025 2022 2023 2024 1-3Q2024 1-3Q2025

R&D Costs as % of Total Revenue Net Finance Costs as % of Total Revenue (2)

0.9%0.9%

3.9%3.8%3.8%3.9%0.8%

2.9%

0.1%0.1%

2022 2023 2024 1-3Q2024 1-3Q2025 2022 2023 2024 1-3Q2024 1-3Q2025

1. Excluding share-based compensation expenses recognized in administrative expenses 10

2. Net finance costs including interest expenses on bank borrowings and lease liabilities interest income and bank wealth management products related gains or lossesExpect to Continue to Achieve Positive Free Cash Flow in 2025

RMB mm

29502865

2754

2577

2436

2143

2041

1901

1771

1499

2022 2023 2024 1-3Q2024 1-3Q2025

Net Operating Cash Flow CAPEX

111-3Q2025 Non-IFRSs Adjusted Net Profit

RMB mm 1-3Q2025 1-3Q2024

Net Profit 1141 1422

Add:

Share-based Compensation Expenses 52 84

Convertible Bonds Related Gains - (6)

Foreign Exchange Related Losses 31 32

Amortization of Intangible Assets from Acquisitions 2 -

Realized and Unrealized Gains From Equity Investments 0 (468)

One-off Loss Made by Pharmaron Shanghai Co.-44

Ltd. due to the Business Close

Non-IFRSs Net Profit 1227 1107

Data are rounded to the nearest million 12Acquisition of Biortus to Enhance Our SBDD & Protein Science Service Capabilities

Biortus provides key structural biology data to support SBDD for global customers. Its core competitiveness is

built on highly efficient complex target protein production wide-coverage X-ray crystallography and

state-of-the-art cryo-EM structure capabilities

* Biortus has a strong

customer base and is * Further strengthening

poised to reach more Pharmaron’s protein

global customers Global Protein production & analysis

through Pharmaron's Customers Production capabilities

integrated platform

* Synergies between * Leveraging

Biortus’s structural Pharmaron’s AI

biology services & technology platform

Bioscience AI

Pharmaron’s Services Technology to improve data

bioscience services analysis capabilities

132025 Outlook

The evolving healthcare demands and technological innovations will sustain the

development of our industry. Global customer demand continued to demonstrate

resilience while demand from China customers is expected to recover gradually

Continue to develop our end-to-end fully integrated and multiple modalities-capable

services platform with global footprints to further support our customers in improving

the efficiency and flexibility of their pharmaceutical R&D and manufacturing needs

Expect to deliver 12~16% revenue growth in 2025

Guidance does not include the potential contribution from the Biortus acquisition

Disclaimer: These forward-looking statements reflects the current view of the Company with respect to future events are based on a number of assumptions about

the Company’s operations and factors beyond the Company’s control and are subject to significant risks and uncertainties and accordingly actual results may differ 14

materially from these forward-looking statementsTHANK YOU